FDA Inspection 1342072 — BrightGene BioMedical Technology Co., Ltd.
The FDA completed an inspection of BrightGene BioMedical Technology Co., Ltd. on Sep 9, 2026 in Suzhou. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Sep 9, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Suzhou (China)